Publications: Mrs Charlotte Ackerman

Jackson-Spence F, Ackerman C, Jones R, Toms C, Jovaisaite A, Young M, Hussain S, Protheroe A et al. ( 2024 ) . Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel . Urologic Oncology Seminars and Original Investigations vol. 42 , ( 11 ) 372.e1 - 372.e10 .

Jackson-Spence F, Rodriguez CS, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Vidal MJM, Markovets A et al. ( 2023 ) . 1888P 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer . Annals of Oncology vol. 34 ,

Jackson-Spence F, Ackerman C, Szabados B, Toms C, Jovaisaite A, Gunnell R, Suárez C, Larkin J et al. ( 2023 ) . DNA alterations in papillary renal cancer . Journal of Clinical Oncology vol. 41 , ( 6_suppl ) 725 - 725 .

Jackson-Spence FE, Powles T, Loriot Y, Toms C, Jovaisaite A, Choy J, Szabados BE, Nudds H et al. ( 2022 ) . P126 Trial In Progress: DISCUS: A randomized phase II study comparing 3 vs. 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer . European Urology Open Science vol. 45 ,

Tan WS, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P, Phull J, Hunter-Campbell P et al. ( 2022 ) . Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial . European Urology vol. 83 , ( 6 ) 497 - 504 .

Szabados B, Duncan S, Choy J, Jackson-Spence F, Toms C, Trevisan G, Berney DM, Powles T et al. ( 2022 ) . Androgen Receptor Expression Is a Predictor of Poor Outcome in Urothelial Carcinoma . Frontiers in Urology vol. 2 ,

Schmid P, Gomez-Pardo P, Wheatley D, Roy P, Krabisch P, Thill M, Ledwidge S, Thompson A et al. ( 2021 ) . 208P ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC . Annals of Oncology vol. 32 , s449 - s450 .

Jackson-Spence FE, Ackerman C, Khan M, Grant M, Soosaipillai G, Nally E, Choy J, Powles TB et al. ( 2021 ) . P0461 The role of angiogenic signatures in advanced urothelial carcinoma (aUC) treated with VEGF-targeted therapy . European Urology vol. 79 ,

Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S et al. ( 2019 ) . Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy . European Urology Focus vol. 6 , ( 5 ) 999 - 1005 .

Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al. ( 2017 ) . LBA53 A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers . Annals of Oncology vol. 28 ,

Powles T, de Liaño AG, Ackerman C ( 2017 ) . Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed . European Urology vol. 72 , ( 5 ) e137 - e138 .

Shepherd STC, Hall P, Brown JE, Larkin JMG, Jones RJ, Ralph C, Hawkins RE, Chowdhury S et al. ( 2017 ) . Can dynamic changes in prognostic markers predict survival in patients receiving VEGF-targeted therapy in clear cell renal cell carcinoma? . Journal of Clinical Oncology . vol. 35 , e16061 - e16061 .

Ackerman C, Mariathasan S, Nickles D, Gomez De Liano Lista A, Wimalasingham AG, Szabados B, Powles T ( 2017 ) . Molecular subtyping of metastatic urothelial bladder cancer . Journal of Clinical Oncology . vol. 35 , 326 - 326 .

Powles T, Huddart RA, Elliott T, Sarker S-J, Ackerman C, Jones R, Hussain S, Crabb S et al. ( 2017 ) . Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer . J Clin Oncol vol. 35 , ( 1 ) 48 - 55 .

Powles THOMAS, Huddart RA, Elliott T, SARKER S-J, Ackerman CHARLOTTE, Jones R, Hussaine S, Crabb S et al. ( 2016 ) . A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients . Journal of Clinical Oncology

Powles T, Sarwar N, Stockdale A, Sarker S-J, Boleti E, Protheroe A, Jones R, Chowdhury S et al. ( 2016 ) . Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer . JAMA Oncology vol. 2 , ( 10 ) 1303 - 1309 .

Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E et al. ( 2016 ) . A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK) . Annals of Oncology vol. 27 , ( 5 ) 880 - 886 .

Powles T, Hussain SA, Protheroe A, Birtle A, Chakraborti PR, Huddart R, Jagdev S, Bahl A et al. ( 2016 ) . PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours . Journal of Clinical Oncology . vol. 34 , 430 - 430 .

Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A et al. ( 2013 ) . The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer . Clinical Cancer Research vol. 19 , ( 24 ) 6924 - 6934 .

Powles T, Kayani I, Blank CU, Chowdhury S, Horenblas S, Sarwar N, Nathan PD, Boleti E et al. ( 2010 ) . The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer . Journal of Clinical Oncology vol. 28 , ( 15_suppl ) 4603 - 4603 .